Advocacy intelligence hub — real-time data for patient organizations
TICAROS Co., Ltd. — PHASE2
New York State Psychiatric Institute — NA
Epkinly: FDA approved
in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL)
Sun Yat-sen University — EARLY_PHASE1
Gottfried von Keudell, MD PhD — PHASE2
Gustave Roussy, Cancer Campus, Grand Paris — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance5
Patient Assistance Programs6
Breyanzi
Juno Therapeutics, Inc.
Rituxan
Genentech, Inc.
Rituxan SC
Genentech, Inc.
Zydelig
Gilead Sciences, Inc.
Ukoniq
TG Therapeutics, Inc.
GAZYVA
Genentech Inc., a member of the Roche Group
Epkinly
(epcoritamab-bysp)Orphan drugGenmab US, Inc.
Bispecific CD20-directed CD3 T Cell Engager [EPC]
12.1 Mechanism of Action Epcoritamab-bysp is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells ...
Lunsumio
(mosunetuzumab-axgb)Orphan drugGenentech, Inc.
12.1 Mechanism of Action Mosunetuzumab-axgb is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cell...
Kymriah
(tisagenlecleucel)Orphan drugNovartis Pharmaceuticals Corporation
CD19-directed Chimeric Antigen Receptor [EPC]
12.1 Mechanism of Action KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy which involves reprogramming a patient’s own ...
Tazverik
(tazemetostat)Orphan drugEpizyme, Inc.
12.1 Mechanism of Action Tazemetostat is an inhibitor of the methyltransferase, EZH2, and some EZH2 gain-of-function mutations including Y646X, A682G,...
Yescarta
(axicabtagene ciloleucel)Orphan drugKite Pharma, Inc.
CD19-directed Chimeric Antigen Receptor [EPC]
12.1 Mechanism of Action YESCARTA, a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and nor...
ALIQOPA
(copanlisib)Orphan drugBayer US LLC
Zydelig
(idelalisib)Orphan drugGilead Sciences, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Idelalisib is an inhibitor of phosphatidylinositol 3-kinase, PI3Kδ, which is expressed in normal and malignant B-cells. Idela...
MONJUVI
(tafasitamab-cxix)Orphan drugstandardIncyte Corporation
12.1 Mechanism of Action Tafasitamab-cxix is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and matur...
Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib.
Linperlisib, a highly selective PI3K-δ inhibitor, was firstly approved in China in November 2022 for the treatment of patients with relapsed or refractory follicular lymphoma (r/r FL) who had re...
Cell-free chromatin state tracing reveals disease origin and therapy responses.
Cell-free DNA in blood originates from fragmented chromatin released by dying cells from both healthy and diseased tissues 1,2 . These fragments carry rich molecular modalities that can reveal patholo...
Spatial profiling uncovers multicellular dynamics in early relapse of hepatitis B virus-associated follicular lymphoma.
Hepatitis B virus (HBV) infections are associated with an increased risk of B-cell lymphomas, including follicular lymphoma (FL). Chronic HBV infection and shifts in infection status following treatme...
Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.
Follicular lymphoma (FL) has historically been regarded as incurable, with patients experiencing late relapses after initial chemoimmunotherapy treatment. To provide 15-year follow-up data from the SW...
Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to ...
Biomarkers Informed by Single-Cell and Spatial Transcriptomics-Biomarkers for Grade 3 Follicular Lymphoma.
Follicular lymphoma (FL) patients have variable outcomes, underscoring the need for biomarkers for improved risk stratification. Current FL grading systems, based on subjective centroblast counts, suf...
Mikhail Samsonov
R-Pharm
Prof. Dr. Michael Schmitt
University Hospital Heidelberg, Department V
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Adam J Olszewski, MD
Yale Cancer Center
📍 New Haven, Connecticut
Prof. Dr. Andreas Kulozik
University Hospital Heidelberg, University Medical Center for Children and Adolescents
Mary Horowitz, MD, MS, LCSW
Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin
📍 CHICAGO, IL